List of Excipients in Branded Drug REVLIMID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Celgene Corporation	REVLIMID	lenalidomide	59572-402	ANHYDROUS LACTOSE
Celgene Corporation	REVLIMID	lenalidomide	59572-402	CELLULOSE, MICROCRYSTALLINE
Celgene Corporation	REVLIMID	lenalidomide	59572-402	CROSCARMELLOSE SODIUM
Celgene Corporation	REVLIMID	lenalidomide	59572-402	MAGNESIUM STEARATE

REVLIMID Excipient Strategy and Commercial Opportunities for Lenalidomide

Last updated: August 31, 2026

Revlimid, the brand name for lenalidomide, is a mature oral solid-dose product with substantial remaining commercial value despite generic entry. Its excipient strategy is relatively simple: immediate-release hard gelatin capsules use a conventional lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate blend. The largest opportunities are therefore in compliant generic manufacturing, excipient supply, packaging, handling controls, and differentiated dosage forms rather than in novel excipient chemistry.

Lenalidomide is a potent immunomodulatory drug used in multiple myeloma, myelodysplastic syndromes associated with deletion 5q, mantle cell lymphoma, and follicular and marginal zone lymphomas under U.S. labeling. Bristol Myers Squibb markets Revlimid after acquiring Celgene. U.S. generic competition began in a limited manner in 2022, while patent settlements and regulatory exclusivities have delayed unrestricted competition in some strengths and indications [1][2].

What excipients are used in Revlimid capsules?

Revlimid capsules use a conventional immediate-release formulation. The active ingredient is lenalidomide, and the core excipients identified in U.S. labeling are:

Formulation element	Excipient or material	Primary function
Diluent	Anhydrous lactose	Bulk, powder flow, capsule fill weight
Filler and compression aid	Microcrystalline cellulose	Dilution, packing, content uniformity
Disintegrant	Croscarmellose sodium	Rapid capsule-content dispersion
Lubricant	Magnesium stearate	Powder processing and ejection
Capsule shell	Gelatin	Hard capsule structure
Opacifier or colorant	Titanium dioxide and colorants, depending on strength	Product identification and light protection
Printing system	Pharmaceutical ink	Strength and product identification

The precise colorant and imprint configuration varies by capsule strength. The FDA label identifies the dosage strengths as 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg [1].

The formulation is commercially efficient because the active dose is low relative to the capsule fill. That creates a major content-uniformity requirement. Lenalidomide manufacturers must control segregation, blending, sampling, and capsule-filling variability. The excipients must support homogeneous distribution of a low-dose, potent active ingredient across the batch.

How does the Revlimid excipient strategy affect generic manufacturing?

The main technical challenge is not dissolution. It is reliable low-dose uniformity under potent-compound containment requirements.

A generic manufacturer normally seeks to replicate the reference product's qualitative and quantitative excipient profile as closely as practical. A close composition can reduce formulation risk, simplify comparative dissolution work, and limit the number of variables in an ANDA bioequivalence program. FDA's product-specific guidance and ANDA requirements determine the final evidence package [3].

Low-dose content uniformity

Lenalidomide represents a small percentage of the total capsule fill. Manufacturers should evaluate:

• Ordered blending and geometric dilution for the active ingredient.
• Particle-size distribution of lenalidomide and each major excipient.
• Blend segregation during transfer and hopper storage.
• Sampling plans capable of detecting localized concentration differences.
• Capsule-fill weight variation.
• Assay and uniformity of dosage units across the batch.
• Electrostatic behavior and powder adhesion to processing equipment.

Microcrystalline cellulose can improve bulk and packing properties, while anhydrous lactose provides a predictable diluent system. Croscarmellose sodium supports disintegration but can affect powder flow and moisture behavior. Magnesium stearate requires controlled addition and mixing time because over-lubrication can alter wetting and dissolution.

Potent-compound containment

Lenalidomide has reproductive toxicity and requires controlled handling. The National Institute for Occupational Safety and Health lists hazardous-drug controls relevant to pharmaceutical production and healthcare handling [4]. Commercial manufacturers must manage:

• Closed or contained dispensing.
• Dedicated or validated cleaning procedures.
• Personnel exposure monitoring.
• Segregated waste handling.
• High-efficiency filtration and environmental controls.
• Specialized packaging and labeling.
• Cross-contamination prevention.

This favors manufacturers with established oncology and high-potency oral-solid infrastructure. It also creates opportunities for contract development and manufacturing organizations that can handle low-dose cytotoxic or teratogenic compounds at commercial scale.

What commercial opportunities exist for Revlimid excipient suppliers?

The strongest excipient opportunity is dependable, qualified supply rather than a radically new formulation.

Anhydrous lactose

Anhydrous lactose is a practical commercial target because it provides bulk without introducing the moisture associated with hydrated lactose. Suppliers can compete on:

• Particle-size consistency.
• Low bioburden and endotoxin control.
• Flowability.
• Global regulatory documentation.
• Lot-to-lot uniformity.
• Supply security for generic manufacturers.

A lactose-free formulation could address patients with lactose intolerance, but it would be less attractive for a conventional ANDA if it creates unnecessary differences from the reference product. A lactose-free product could be more relevant to a 505(b)(2) development program or a differentiated international product, subject to clinical and regulatory requirements.

Microcrystalline cellulose

Microcrystalline cellulose is likely to remain a core excipient because it supports low-dose powder distribution and fill-weight control. Suppliers with narrow particle-size distributions and strong functionality data can compete for generic lenalidomide programs.

The commercial value is highest when the supplier can provide direct-compression or capsule-filling grades with validated performance in potent-drug blends. Technical service, not only price, matters because changing cellulose grade can affect blend density, segregation, and capsule fill.

Croscarmellose sodium

Croscarmellose sodium supports rapid capsule-content breakup. Its value is tied to consistent swelling capacity, substitution level, particle size, and moisture profile. A generic manufacturer may use a different grade, but the replacement must preserve comparative dissolution and stability performance.

Magnesium stearate

Magnesium stearate is inexpensive but process-sensitive. Suppliers can differentiate through controlled surface area, fatty-acid composition, particle size, and low variability. The main risk is excessive lubrication, which can slow dissolution or weaken interparticle bonding in a related compressed dosage form.

Capsule shells and printing systems

Hard gelatin capsule suppliers can capture value through:

• Color-matched shells for multiple strengths.
• Low-variability dimensions.
• Low moisture variation.
• Reliable printing adhesion.
• Tamper-evident packaging compatibility.
• Supply to markets requiring alternative capsule-shell specifications.

Vegetarian capsules made from hypromellose could support a differentiated product, but a shell change may require additional comparative work. It is not automatically a low-risk substitution for a standard ANDA.

What formulation patents protect Revlimid?

Revlimid's commercial protection has historically relied on a combination of composition, polymorph, formulation, and method-of-use patents. The key protection has not been limited to the capsule excipient blend.

Public patent records and FDA Orange Book listings should be reviewed by strength, indication, and approved labeling because the relevant patents can differ by product presentation and use [2][5].

Protection category	Commercial relevance
Lenalidomide compound and chemical claims	Broad early protection; largely expired or no longer the main barrier
Solid-state or polymorph claims	May protect the active ingredient's commercially useful form
Capsule or formulation claims	Can restrict specific excipient combinations or dosage-form configurations
Method-of-use claims	Can delay generic labeling for protected indications
Distribution and safety-system controls	May affect market access even when formulation patents are weak
Pediatric exclusivity or regulatory exclusivity	Can extend effective protection beyond an underlying patent term

The excipient blend itself may be difficult to protect broadly if it uses well-known materials in conventional proportions. Stronger formulation claims require a defensible relationship between composition and performance, such as improved stability, dissolution, manufacturability, or bioavailability.

When does Revlimid lose exclusivity?

Revlimid's effective loss of exclusivity is staged rather than a single date.

The original lenalidomide composition protection expired before generic entry, but later patents and settlement agreements controlled the timing and scale of competition. U.S. generic lenalidomide products entered under agreed conditions beginning in 2022. Full generic availability depends on the product, indication, patent claims, settlement terms, and applicable regulatory exclusivity [1][2].

Revlimid exclusivity timeline

Period	Event
2005	FDA approval of Revlimid for multiple myeloma-related use
2010s	Additional indications and later-generation patent and method-of-use protections
2017	Important early lenalidomide compound protection reached expiration
2018-2021	Patent litigation and settlements with ANDA applicants shaped entry timing
2022	Limited U.S. generic lenalidomide launches began
2022 onward	Additional generic suppliers entered under settlement and regulatory conditions
Through the late 2020s	Certain patent, exclusivity, and indication restrictions can continue to affect unrestricted competition

Patent expiry dates must be checked against the current Orange Book, FDA approvals, pediatric extensions, and litigation records. A single "Revlimid patent expiration date" can be misleading because different claims cover different uses and products.

Which companies challenged Revlimid patents?

Publicly reported ANDA challenges involved multiple generic companies, including Teva, Natco, Dr. Reddy's Laboratories, and Zydus, among others. Celgene and later Bristol Myers Squibb brought patent litigation against ANDA applicants under the Hatch-Waxman framework. Several disputes ended in settlements that established permitted entry dates or other commercial conditions [2][6].

Paragraph IV challenges created the pathway for generic applicants to contest patent validity or non-infringement before expiration. They also triggered the statutory 30-month stay for FDA approval in applicable cases. The practical result was staggered entry rather than immediate broad substitution.

What is the Orange Book status of Revlimid?

Revlimid is an FDA-listed small-molecule drug, not a biologic. Its relevant U.S. patent information is recorded in the Orange Book, subject to updates and corrections. Orange Book review should cover:

• Drug product and dosage strength.
• Listed patents.
• Patent use codes.
• Pediatric exclusivity.
• Generic approvals.
• Approval dates and tentative approvals.
• Whether a patent applies to all indications or only selected uses.

The Orange Book is the primary regulatory reference for listed patents, but it does not replace review of court dockets, settlement agreements, or the full patent claims [5].

What generic entry risks exist for Revlimid?

Generic entry risk is high for the core immediate-release capsule because:

1. The dosage form is conventional.
2. The excipient system uses widely available materials.
3. Multiple manufacturers have regulatory experience with lenalidomide.
4. The API does not require a complex delivery technology.
5. Established settlement pathways have already enabled limited generic supply.

The remaining risk is commercial rather than purely technical. Generic companies must manage high-potency containment, restricted distribution requirements, pharmacovigilance, and possible indication carve-outs. Pricing pressure will increase as more approved suppliers enter, but access restrictions and patent-specific labeling can slow substitution.

Is there biosimilar risk for Revlimid?

No. Revlimid contains lenalidomide, a chemically synthesized small molecule. It is subject to the generic drug pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive products are abbreviated new drug applications, authorized generics, and potentially differentiated 505(b)(2) products. Biosimilar development, interchangeability, and biologic reference-product exclusivity do not apply.

What formulation opportunities remain for lenalidomide?

The most credible opportunities are targeted at convenience, safety, and manufacturing rather than improved systemic exposure.

Alternative oral dosage forms

Potential development concepts include:

• Smaller capsules for patients with swallowing difficulty.
• Sprinkle or dispersible products.
• Oral liquids for selected populations.
• Modified packaging that reduces handling exposure.
• Unit-dose blister systems.
• Age- or weight-adjusted presentations.

Each change can create a new regulatory program. A liquid or dispersible form may require new stability, dose-uniformity, extractables and leachables, palatability, and bioequivalence work.

Excipient substitution

A lactose-free, gelatin-free, or low-allergen presentation may have commercial value in selected markets. However, excipient substitution can create new risks involving:

• Different powder density.
• Blend segregation.
• Moisture uptake.
• Dissolution changes.
• Capsule-shell compatibility.
• Stability and impurity formation.
• Patient tolerability.

The business case is strongest where the change solves a specific access or manufacturing problem and supports defensible differentiation.

Packaging as a commercial differentiator

Packaging is underappreciated in potent oral oncology products. Unit-dose blisters, child-resistant systems, tamper evidence, moisture barriers, and clear strength differentiation can reduce medication errors and occupational exposure. Packaging changes can also support hospital, specialty-pharmacy, and international distribution requirements.

How strong is the Revlimid patent estate?

The estate is strong historically but weaker as a barrier to the core capsule than during the product's growth period.

Factor	Assessment
Chemical complexity	Low to moderate
Dosage-form complexity	Low
API manufacturing barriers	Moderate because of quality, potency, and supply controls
Core excipient defensibility	Low unless tied to specific performance claims
Method-of-use protection	Historically significant
Patent litigation exposure	High during the principal ANDA challenge period
Generic substitution risk	High and rising
Biosimilar exposure	Not applicable
Manufacturing-containment barrier	Moderate to high

The strongest residual commercial defenses are likely to be indication-specific rights, regulated distribution and safety controls, manufacturing quality, and supply reliability rather than the basic excipient composition.

How does Revlimid compare with competing multiple-myeloma products?

Product	Active ingredient	Dosage form	Competitive issue
Revlimid	Lenalidomide	Immediate-release capsule	Generic entry and indication-specific patent protection
Pomalyst/Imnovid	Pomalidomide	Capsule	Similar immunomodulatory class and high-potency handling
Thalomid	Thalidomide	Capsule	Older immunomodulatory therapy with substantial safety controls
Velcade	Bortezomib	Injectable	Different administration and manufacturing model
Darzalex	Daratumumab	Injectable	Biologic competition, not generic substitution
Kyprolis	Carfilzomib	Injectable	Parenteral administration and different IP profile

Revlimid's principal structural advantage has been oral administration and broad use in combination regimens. Generic entry reduces that advantage's economic value but does not eliminate demand in established treatment pathways.

What revenue exposure does Revlimid face?

Revlimid remains a major product for Bristol Myers Squibb, but revenue is exposed to generic erosion, negotiated entry, and migration to newer myeloma therapies. BMS reported multi-billion-dollar annual Revlimid revenue in its recent filings, while identifying expected erosion from generic competition as a material commercial factor [2].

The most exposed revenue is in high-volume multiple myeloma use. Revenue persistence can be higher in indications where:

• Generic labeling is carved out.
• Physicians maintain branded prescribing for specific regimens.
• Distribution controls remain operationally important.
• Patients are stable on an established brand product.
• Payer contracts delay substitution.

What licensing and partnering opportunities exist?

Licensing opportunities are more attractive in manufacturing and delivery technology than in the base Revlimid capsule.

Potential deal structures include:

• Regional rights for approved or generic lenalidomide products.
• Contract manufacturing partnerships for contained oral-solid production.
• Excipient supply agreements with performance specifications.
• Packaging and specialty-pharmacy distribution partnerships.
• 505(b)(2) development collaborations for alternative dosage forms.
• Technology licenses for low-dose blending, containment, or automated inspection.
• Authorized-generic arrangements.

Any transaction should separate rights to the active ingredient, formulation, regulatory dossier, trademarks, distribution systems, and patents. A license covering only a capsule formulation may provide limited protection if competing products use non-infringing excipient systems.

Key Takeaways

• Revlimid uses a conventional immediate-release hard gelatin capsule formulation.
• Core excipients are anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.
• The primary technical issue is low-dose content uniformity under potent-compound containment requirements.
• Generic entry risk is high because the dosage form is simple and multiple ANDA applicants have entered the market.
• Revlimid is a small-molecule drug, so biosimilar risk does not apply.
• Excipient suppliers can compete through grade consistency, regulatory support, supply reliability, and technical service.
• Differentiated opportunities include lactose-free, gelatin-free, sprinkle, liquid, smaller-capsule, and unit-dose packaging concepts.
• Formulation patents are less commercially durable than method-of-use, polymorph, and settlement-based protections.
• Patent expiry must be assessed by claim, indication, strength, and Orange Book listing rather than by one product-wide date.
• The highest-value commercial opportunities are contained manufacturing, specialty packaging, regional generic supply, and differentiated oral delivery.

FAQs

Can a generic lenalidomide manufacturer use different excipients from Revlimid?

Yes, subject to FDA requirements. The manufacturer must demonstrate that the formulation performs appropriately and meets applicable pharmaceutical equivalence, quality, dissolution, stability, and bioequivalence standards.

Is anhydrous lactose essential to Revlimid's performance?

It is a listed excipient in the reference formulation, but it is not necessarily mandatory for every generic product. Substitution can affect density, moisture, flow, uniformity, and dissolution.

Does a lactose-free lenalidomide capsule create patent freedom to operate?

No. Excipient substitution may avoid a narrow formulation claim, but it does not eliminate method-of-use, polymorph, process, or other patent risks.

Can lenalidomide be developed as an oral liquid?

Potentially, but an oral liquid would require a separate formulation and regulatory strategy. Chemical stability, dose uniformity, container compatibility, palatability, and handling exposure would be central development issues.

Are Revlimid capsules manufactured under ordinary pharmaceutical containment controls?

No. Lenalidomide requires controls appropriate to a potent drug with reproductive-toxicity concerns. Manufacturing, packaging, dispensing, and healthcare handling must follow applicable hazardous-drug and product-specific requirements.

References

1. U.S. Food and Drug Administration. (2024). Revlimid (lenalidomide) capsules prescribing information. Bristol Myers Squibb.

2. Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb.

3. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. FDA.

4. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings, 2023. Centers for Disease Control and Prevention.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. District Court and U.S. Court of Appeals for the Federal Circuit. (2018-2024). Celgene Corporation and Bristol Myers Squibb patent litigation records concerning lenalidomide ANDA products. PACER and Federal Circuit opinions.